1200 Participants Needed

Opevesostat for Prostate Cancer

Recruiting at 293 trial locations
TF
Overseen ByToll Free Number
Age: Any Age
Sex: Any
Trial Phase: Phase 3
Sponsor: Merck Sharp & Dohme LLC
Must be taking: Androgen deprivation therapy
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

What is the purpose of this trial?

This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) and to radiographic progression-free survival (rPFS) per Prostate Cancer Working Group (PCWG) Modified Response Evaluation Criteria In Solid Tumors (RECIST 1.1) as assessed by blinded independent central review (BICR) in participants with mCRPC previously treated with next-generation hormonal agent (NHA) and taxane-based chemotherapy. It is hypothesized that opevesostat is superior with respect to OS and rPFS per PCWG Modified RECIST 1.1 as assessed by BICR in androgen receptor ligand binding domain (AR LBD) mutation-negative and -positive participants.

Will I have to stop taking my current medications?

The trial requires stopping certain medications before participating. You must stop using herbal products with hormonal activity, 5-αreductase inhibitors, and certain other medications like strong CYP3A4 inducers and P-gp inhibitors at least 2-4 weeks before starting the study.

What data supports the effectiveness of the drug Opevesostat for prostate cancer?

Research shows that abiraterone acetate, often used with prednisone, improves survival in patients with metastatic castration-resistant prostate cancer. Additionally, combining abiraterone with enzalutamide and androgen deprivation therapy has been shown to improve outcomes for these patients.12345

Is Opevesostat safe for humans?

Abiraterone acetate, a component of Opevesostat, has been used safely in combination with other drugs for treating prostate cancer, but it may increase the risk of metabolic (related to the body's chemical processes) and cardiovascular (heart and blood vessel) issues.12567

What makes the drug Opevesostat for prostate cancer unique?

Opevesostat, combined with Abiraterone acetate and Enzalutamide, offers a novel approach by potentially enhancing the effectiveness of existing prostate cancer treatments. This combination targets different pathways involved in cancer progression, which may improve outcomes compared to using these drugs individually.12589

Research Team

MD

Medical Director

Principal Investigator

Merck Sharp & Dohme LLC

Eligibility Criteria

This trial is for men with advanced prostate cancer that has spread and resisted treatment, including hormone therapy and up to two chemo treatments. Participants must have a specific performance status, which measures how well they can do daily activities, and cannot have small cell prostate cancer histology.

Inclusion Criteria

My prostate cancer is confirmed without being a small cell type.
My prostate cancer got worse while on hormone therapy or after surgery to remove my testicles, within the last 6 months.
My cancer has spread, as shown by bone scan or CT/MRI.
See 7 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive opevesostat or alternative NHA until progression

Up to 54 months
Regular visits as per protocol

Follow-up

Participants are monitored for safety and effectiveness after treatment

Up to 54 months

Treatment Details

Interventions

  • Abiraterone acetate
  • Dexamethasone
  • Enzalutamide
  • Fludrocortisone acetate
  • Hydrocortisone
  • MK-5684
  • Prednisone
Trial OverviewThe study compares MK-5684 to other medications like abiraterone acetate or enzalutamide in improving survival without cancer progression. It's open-label, meaning everyone knows what treatment they're getting, and it uses imaging reviews by experts who don't know the patients' group assignments.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: OpevesostatExperimental Treatment4 Interventions
Participants receive opevesostat 5 mg by oral tablets twice daily (bid) plus dexamethasone 1.5 mg by oral tablets once daily (qd) and 0.1 mg fludrocortisone acetate by oral tablet qd until progression. Hydrocortisone 100 mg (oral or intramuscular \[IM\]) dose will also be provided to participants for use as rescue medication.
Group II: Abiraterone Acetate or EnzalutamideActive Control3 Interventions
Participants receive abiraterone 1000 mg qd by oral tablets plus prednisone 5 mg bid by oral tablets or enzalutamide 160 mg qd by oral tablets.

Abiraterone acetate is already approved in European Union, United States, Canada, Japan for the following indications:

🇪🇺
Approved in European Union as Zytiga for:
  • Metastatic castration-resistant prostate cancer
🇺🇸
Approved in United States as Zytiga for:
  • Metastatic castration-resistant prostate cancer
  • High-risk metastatic hormone-sensitive prostate cancer
🇨🇦
Approved in Canada as Zytiga for:
  • Metastatic castration-resistant prostate cancer
🇯🇵
Approved in Japan as Zytiga for:
  • Metastatic castration-resistant prostate cancer

Find a Clinic Near You

Who Is Running the Clinical Trial?

Merck Sharp & Dohme LLC

Lead Sponsor

Trials
4,096
Recruited
5,232,000+
Chirfi Guindo profile image

Chirfi Guindo

Merck Sharp & Dohme LLC

Chief Marketing Officer since 2022

Degree in Engineering from Ecole Centrale de Paris, MBA from New York University Stern School of Business

Robert M. Davis profile image

Robert M. Davis

Merck Sharp & Dohme LLC

Chief Executive Officer since 2021

JD from Northwestern University Pritzker School of Law, MBA from Northwestern University Kellogg Graduate School of Management, Bachelor's in Finance from Miami University

Orion Corporation, Orion Pharma

Industry Sponsor

Trials
140
Recruited
45,200+
Liisa Hurme profile image

Liisa Hurme

Orion Corporation, Orion Pharma

Chief Executive Officer since 2022

PhD in Biochemistry, University of Helsinki

Hilpi Rautelin profile image

Hilpi Rautelin

Orion Corporation, Orion Pharma

Chief Medical Officer since 2023

MD, University of Turku

Findings from Research

In a study involving 1919 patients with metastatic prostate cancer, the addition of abiraterone acetate to standard androgen deprivation therapy significantly improved overall survival, with a median survival of 76.6 months compared to 45.7 months for standard care alone.
Combining both abiraterone and enzalutamide did not provide additional survival benefits over abiraterone alone, and it was associated with higher rates of severe side effects, suggesting that this combination should be avoided in long-term treatment plans.
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.Attard, G., Murphy, L., Clarke, NW., et al.[2023]
Oral abiraterone acetate (Zytiga®) significantly improves overall survival and progression-free survival in patients with metastatic castration-resistant prostate cancer (CRPC) when used with prednisone, compared to a placebo.
The treatment is specifically effective for patients who have already undergone docetaxel-containing chemotherapy, highlighting its role as a subsequent therapy in advanced prostate cancer management.
Abiraterone acetate: a guide to its use in metastatic castration-resistant prostate cancer.Scott, LJ., Yang, LPH., Lyseng-Williamson, KA.[2021]
In a study of 38 patients with metastatic castration-resistant prostate cancer (mCRPC) who had previously been treated with docetaxel and enzalutamide, abiraterone and prednisolone showed modest antitumor activity, with only 8% of patients achieving a significant PSA response.
The treatment was well tolerated, but the median progression-free survival was only 2.7 months, indicating limited effectiveness in this patient population.
Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100).Loriot, Y., Bianchini, D., Ileana, E., et al.[2023]

References

Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol. [2023]
Abiraterone acetate: a guide to its use in metastatic castration-resistant prostate cancer. [2021]
Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). [2023]
Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment. [2022]
Pharmacokinetics and bioequivalence of generic and branded abiraterone acetate tablet: a single-dose, open-label, and replicate designed study in healthy Chinese male volunteers. [2022]
Risk of Metabolic and Cardiovascular Adverse Events With Abiraterone or Enzalutamide Among Men With Advanced Prostate Cancer. [2023]
Enzalutamide for patients with metastatic castration-resistant prostate cancer. [2020]
Adoption of Abiraterone and Enzalutamide by Urologists. [2021]
Oral formulation strategies to improve the bioavailability and mitigate the food effect of abiraterone acetate. [2020]